Posted by Michael Wonder on 31 Jul 2017
Express Scripts to cover Mylan's EpiPen, exclude rivals
1 August 2017 - Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favour drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.
The nation's largest pharmacy benefit manager said it was excluding alternatives to the auto-injector made by Impax Laboratories Inc, privately held Kaleo and A-S Medication from its widely used list of covered drugs.
Express Scripts has been excluding certain medicines from its coverage list or formulary since 2014, citing concern about costs to its health insurers and corporate customers.
